Abstract
The paper by Fearon and coworkers in this issue illustrates the expanding and exciting role of DNA technology in clinical medicine.1 First applied less than a decade ago, this technology has already contributed to our understanding of the basic mechanisms of disease, provided new means of diagnosis, and made available new therapeutic methods. Perhaps its greatest impact thus far has been felt in genetic disorders, as an increasing number of conditions are becoming amenable to diagnosis, the genes associated with them are being isolated, and their molecular defects are being defined.Several general strategies have been used to characterize the . . .